- Home
- ORKA vs INNV Comparison
ORKA vs INNV Comparison
Compare ORKA & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- INNV
- Stock Information
- Founded
- ORKA 2004
- INNV 2007
- Country
- ORKA United States
- INNV United States
- Employees
- ORKA N/A
- INNV N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- INNV Medical/Nursing Services
- Sector
- ORKA Health Care
- INNV Health Care
- Exchange
- ORKA Nasdaq
- INNV Nasdaq
- Market Cap
- ORKA 429.4M
- INNV 439.5M
- IPO Year
- ORKA N/A
- INNV 2021
- Fundamental
- Price
- ORKA $8.92
- INNV $2.82
- Analyst Decision
- ORKA Strong Buy
- INNV Sell
- Analyst Count
- ORKA 7
- INNV 2
- Target Price
- ORKA $39.67
- INNV $5.00
- AVG Volume (30 Days)
- ORKA 272.6K
- INNV 66.4K
- Earning Date
- ORKA 03-06-2025
- INNV 05-06-2025
- Dividend Yield
- ORKA N/A
- INNV N/A
- EPS Growth
- ORKA N/A
- INNV N/A
- EPS
- ORKA N/A
- INNV N/A
- Revenue
- ORKA N/A
- INNV $806,614,000.00
- Revenue This Year
- ORKA N/A
- INNV $13.21
- Revenue Next Year
- ORKA N/A
- INNV $10.29
- P/E Ratio
- ORKA N/A
- INNV N/A
- Revenue Growth
- ORKA N/A
- INNV 11.91
- 52 Week Low
- ORKA $8.66
- INNV $2.78
- 52 Week High
- ORKA $53.88
- INNV $6.69
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- INNV 28.99
- Support Level
- ORKA N/A
- INNV $2.94
- Resistance Level
- ORKA N/A
- INNV $3.11
- Average True Range (ATR)
- ORKA 0.00
- INNV 0.17
- MACD
- ORKA 0.00
- INNV -0.03
- Stochastic Oscillator
- ORKA 0.00
- INNV 5.49
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.